Pharmacological Management of Cardiorenal Syndromes

House, Andrew A.; Haapio, Mikko; Lassus, Johan; Bellomo, Rinaldo; Ronco, Claudio

doi:10.4061/2011/630809

Cited by 10 publications

(11 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The association of renal insufficiency with DHF leading to the so‐called cardiorenal syndrome (CRS) has received increasing attention . Unfortunately, the clinical management of CRS is largely empiric, and many traditional drugs for heart failure may result in the impairment of renal function because of inappropriate or excessive utilization or their serious side effects .…”

Section: Introductionmentioning

confidence: 99%

Effect of Levosimendan on Estimated Glomerular Filtration Rate in Hospitalized Patients with Decompensated Heart Failure and Renal Dysfunction

Hou

Sun

et al. 2013

Cardiovascular Therapeutics

View full text Add to dashboard Cite

SUMMARYBackground: Only limited data of the long-term effect of levosimendan on renal dysfunction in patients with decompensated heart failure (DHF) have been published previously. To date, there has been no similar study carried out in a Chinese population. Design and Methods: A prospective, randomized, placebo-controlled, and double-blind study was performed to investigate the effect of levosimendan on estimated glomerular filtration rate (eGFR) in DHF patients with renal dysfunction during a 30-day period. Sixty-six patients with left ventricular ejection fraction (LVEF) 40% and eGFR 15-89 mL/min/1.73 m 2 were randomized in a 1:1 ratio to receive a 24-h infusion with levosimendan or placebo. The B-type natriuretic peptide (BNP) and eGFR were determined at baseline and day 1, 3, 7, 14, 30 after the start of treatment. Results: The eGFR levels were obviously enhanced following levosimendan, peaked at 3 days, sustained for at least 14 days, and returned to baseline by day 30 after starting infusion. In contrast, placebo did not induce any significant changes in eGFR levels during the follow-up. In addition, levosimendan resulted in a distinct decrease in BNP levels in comparison with placebo, and the beneficial effect returned to baseline by day 14 and remained so at day 30 postinfusion. Conclusions: A 24-h infusion with levosimendan transiently improved the renal dysfunction compared with placebo in patients with DHF, and its beneficial effects persisted for at least 14 days after the initiation of treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Effect of Levosimendan on Estimated Glomerular Filtration Rate in Hospitalized Patients with Decompensated Heart Failure and Renal Dysfunction

Hou

Sun

et al. 2013

Cardiovascular Therapeutics

View full text Add to dashboard Cite

show abstract

“…Loop diuretics, furosemide, torsemide, and bumetanide, are the most common diuretics used in HF. 49) Loop diuretics cause natriuresis by blocking the Na + , K + , and Cl 2- symport on the thick ascending limb of the loop of Henle, thereby causing reduced volume overload and renal venous congestion. However, their effectiveness is limited in certain patients with CRS for several reasons.…”

Section: Options For Decongestive Treatment In Cardiorenal Syndromementioning

confidence: 99%

Pathophysiology of Cardiorenal Syndrome and Use of Diuretics and Ultrafiltration as Volume Control

Lim

Kim

2021

Korean Circ J

View full text Add to dashboard Cite

Author's summary Acute deterioration in kidney function in the setting of decompensated heart failure, known as cardiorenal syndrome, results from venous congestion. Although diuretics or ultrafiltration are effective measures in decreasing venous congestion and improving symptoms in patients with cardiorenal syndrome, the impact of decongestive therapy on kidney function or mortality remains uncertain. A precise assessment of venous congestion is required to assess the adequacy of patients' response to decongestive therapy and to guide therapeutic decision making.

show abstract

“…A link between renal and cardiovascular diseases could thus be established, once both groups of diseases are significantly associated with BMPs and collagen deposition/degradation. Disorders affecting the cardiovascular or renal systems will most likely involve the other system, giving rise to a pathological condition called cardiorenal syndrome [99,100]. For instance, it is possible that BMPs involved in one of these two groups of diseases end up also affecting the other one, and this interaction may result in one disease leading to the other or both diseases developing simultaneously.…”

Section: Renal Diseasesmentioning

confidence: 99%

Deciphering the disease-related molecular networks using urine proteomics

Bastos

Vlahou

Leite‐Moreira

et al. 2017

TrAC Trends in Analytical Chemistry

View full text Add to dashboard Cite

Despite the large number of studies focused on the impact of diseases on urine proteome, few outputs with clinical meaning were retrieved so far. The goal of this study was to identify the biological processes modulated in urine by distinct diseases to better understand disease pathogenesis and to identify urinary proteins with potential diagnosis value. We searched PubMed and SCOPUS databases for mass spectrometry-based experimental papers and pooled differentially expressed proteins by disease and target organic system. A total of 2572 differentially expressed proteins or peptides were pooled from 89 studies focused on 57 diseases. Data analysis highlighted inflammation as a biological process modulated by all diseases. However, specific inflammatory signatures are associated with specific diseases and/or aetiologies. Moreover, specific biological processes were identified for specific groups of pathologies and unique proteins identified. Overall, integrative data analysis from urine proteomics/peptidomics reinforces the clinical potential of this body fluid for the clinical management of distinct diseases.

show abstract

Pharmacological Management of Cardiorenal Syndromes

Cited by 10 publications

References 77 publications

Effect of Levosimendan on Estimated Glomerular Filtration Rate in Hospitalized Patients with Decompensated Heart Failure and Renal Dysfunction

Effect of Levosimendan on Estimated Glomerular Filtration Rate in Hospitalized Patients with Decompensated Heart Failure and Renal Dysfunction

Pathophysiology of Cardiorenal Syndrome and Use of Diuretics and Ultrafiltration as Volume Control

Deciphering the disease-related molecular networks using urine proteomics

Contact Info

Product

Resources

About